Old Web
English
Sign In
Acemap
>
authorDetail
>
Julie Rytlewski
Julie Rytlewski
Celgene
Cancer research
Medicine
Immunology
Chronic lymphocytic leukemia
Lymphocytic lymphoma
2
Papers
23
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (2)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Rapid Undetectable MRD (uMRD) Responses in Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Treated with Lisocabtagene Maraleucel (liso-cel), a CD19-Directed CAR T Cell Product: Updated Results from Transcend CLL 004, a Phase 1/2 Study Including Patients with High-Risk Disease Previously Treated with Ibrutinib
2019
Blood
Tanya Siddiqi
Jacob D. Soumerai
Kathleen A. Dorritie
Deborah M. Stephens
Peter A. Riedell
Jon E. Arnason
Thomas J. Kipps
Heidi H. Gillenwater
Lucy Gong
Jason A. Dubovsky
Julie Rytlewski
Lin Yang
William G. Wierda
Show All
Source
Cite
Save
Citations (22)
Markers of Initial and Long-Term Responses to Idecabtagene Vicleucel (Ide-Cel; bb2121) in the CRB-401 Study in Relapsed/Refractory Multiple Myeloma
2019
Blood
Ethan G. Thompson
Yue Jiang
Timothy Brandon Campbell
Jaymes Fuller
Shari Kaiser
Afshin Mashadi-Hossein
Julie Rytlewski
Nathan Martin
Olivia Finney
Katja Kleinsteuber
Eric Alonzo
Chetanya Pandya
Amit Agarwal
Kristen Hege
Noopur Raje
Nikhil C. Munshi
Ronald J. Hause
Show All
Source
Cite
Save
Citations (1)
1